-
2022-501697-19-00
5
Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leuke
-
2022-502779-40-99
5
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2024-513724-42-00
10
Medulloblastoma
-
2024-518199-30-00
9
Soft tissue sarcoma patients
-
2024-518990-33-00
11
Age-Associated Macular Degeneration
-
2024-519757-11-00
5
Renal Transplantation, living donor
-
2024-519890-21-00
11
Non-muscle invasive bladder cancer
-
2024-520318-23-00
9
Patients with advanced soft-tissue sarcoma (leiomyosarcoma or malignan
-
2025-520565-51-00
5
small cell lung cancer
-
2025-520711-14-00
4
Allergies
-
2025-521086-28-00
6
CHRONIC INFLAMMATORY RHEUMATIC DISEASE: rheumatoid arthritis or psoria
-
2025-521230-29-00
5
Allergic rhinoconjunctivitis to Dermatophagoides pteronyssinus and Der
-
2025-522586-30-00
5
Psoriatic Arthritis
-
2025-522791-92-00
5
Neoplasm Metastasis
-
2025-523238-17-00
4
Acute myeloid leukemia
-
2025-523180-38-00
4
2026-05-21
Uncontrolled Moderate to Severe Eosinophilic Asthma
-
2025-524498-17-00
10
2026-05-08
Pretreated Unresectable Locally Advanced or Metastatic human epidermal
-
2025-521919-39-00
3
2026-02-10
Resected stage IIB, IIC, or III melanoma requiring adjuvant treatment
-
2025-522070-36-00
5
2025-12-15
immune thrombocytopenia (ITP)
-
2024-512926-27-00
5
2024-12-12
patients with estrogen receptor-positive/human epidermal growth factor
-
2023-503904-10-00
5
2024-06-07
Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity
-
2022-502739-20-00
5
2023-11-16
Active Idiopathic Inflammatory Myopathies (Including Dermatomyositis o
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2024-520006-19-00
6
2021-12-15
Non-muscle invasive bladder cancer